Adjia Hamadjida1, Stephen G Nuara2, Nicolas Veyres1, Imane Frouni1,3, Cynthia Kwan1,3, Lamia Sid-Otmane1,3, Mery-Jane Harraka3, Jim C Gourdon2, Philippe Huot4,5,6,7. 1. Centre de Recherche du Centre Hospitalier de l'Université de Montréal, R09.436, 900 Rue St-Denis, Montreal, QC, H2X 0A9, Canada. 2. Comparative Medicine and Animal Resources Centre, McGill University, Montreal, QC, Canada. 3. Department of Pharmacology, Université de Montréal, Montreal, QC, Canada. 4. Centre de Recherche du Centre Hospitalier de l'Université de Montréal, R09.436, 900 Rue St-Denis, Montreal, QC, H2X 0A9, Canada. p.huot@umontreal.ca. 5. Department of Pharmacology, Université de Montréal, Montreal, QC, Canada. p.huot@umontreal.ca. 6. Unité des Troubles du Mouvement André Barbeau, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada. p.huot@umontreal.ca. 7. Division of Neurology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada. p.huot@umontreal.ca.
Abstract
BACKGROUND: Parkinson's disease (PD) psychosis is encountered in as many as 50% of patients with advanced disease. Treatment options for PD psychosis are few. In fact, only clozapine and pimavanserin have shown efficacy in randomised controlled trials. Clinicians are often reluctant to prescribe the former, due to the risk of agranulocytosis, while the latter is not widely available yet. Because it is already clinically available and exhibits high affinity for serotonin 2A receptors, a target with which both clozapine and pimavanserin interact, we hypothesised that the anti-depressant mirtazapine might be effective to alleviate PD psychosis. METHODS: Here, we tested the anti-psychotic potential of mirtazapine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned common marmoset. Five MPTP-lesioned marmosets exhibiting psychosis-like behaviours were administered L-3,4-dihydroxyphenylalanine (L-DOPA) in combination with mirtazapine (0.1, 1 and 10 mg/kg) or vehicle. We also tested the effect of mirtazapine on L-DOPA-induced dyskinesia. RESULTS: The addition of mirtazapine 10 mg/kg to L-DOPA reduced psychosis-like behaviours by 50% (P < 0.05) and dyskinesia by 29% (P < 0.01), when compared to L-DOPA/vehicle. Importantly, the antipsychotic and antidyskinetic effects of mirtazapine were achieved without hindering L-DOPA anti-parkinsonian action. CONCLUSIONS: Our results suggest that mirtazapine may be effective to alleviate PD psychosis and, because the drug is clinically available, clinical trials that would assess its anti-psychotic efficacy in PD could be rapidly undertaken, hopefully leading to a new treatment option for this debilitating condition.
BACKGROUND:Parkinson's disease (PD) psychosis is encountered in as many as 50% of patients with advanced disease. Treatment options for PD psychosis are few. In fact, only clozapine and pimavanserin have shown efficacy in randomised controlled trials. Clinicians are often reluctant to prescribe the former, due to the risk of agranulocytosis, while the latter is not widely available yet. Because it is already clinically available and exhibits high affinity for serotonin 2A receptors, a target with which both clozapine and pimavanserin interact, we hypothesised that the anti-depressant mirtazapine might be effective to alleviate PD psychosis. METHODS: Here, we tested the anti-psychotic potential of mirtazapine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned common marmoset. Five MPTP-lesioned marmosets exhibiting psychosis-like behaviours were administered L-3,4-dihydroxyphenylalanine (L-DOPA) in combination with mirtazapine (0.1, 1 and 10 mg/kg) or vehicle. We also tested the effect of mirtazapine on L-DOPA-induced dyskinesia. RESULTS: The addition of mirtazapine 10 mg/kg to L-DOPA reduced psychosis-like behaviours by 50% (P < 0.05) and dyskinesia by 29% (P < 0.01), when compared to L-DOPA/vehicle. Importantly, the antipsychotic and antidyskinetic effects of mirtazapine were achieved without hindering L-DOPA anti-parkinsonian action. CONCLUSIONS: Our results suggest that mirtazapine may be effective to alleviate PD psychosis and, because the drug is clinically available, clinical trials that would assess its anti-psychotic efficacy in PD could be rapidly undertaken, hopefully leading to a new treatment option for this debilitating condition.
Authors: Philippe Huot; Tom H Johnston; Katie D Lewis; James B Koprich; M Gabriela Reyes; Susan H Fox; Matthew J Piggott; Jonathan M Brotchie Journal: J Neurosci Date: 2011-05-11 Impact factor: 6.167
Authors: Susan H Fox; Naomi Visanji; Gaby Reyes; Philippe Huot; Jordi Gomez-Ramirez; Tom Johnston; Jonathan M Brotchie Journal: Can J Neurol Sci Date: 2010-01 Impact factor: 2.104
Authors: Peter A Lewitt; Robert A Hauser; Mei Lu; Anthony P Nicholas; William Weiner; Nicholas Coppard; Mika Leinonen; Juha-Matti Savola Journal: Neurology Date: 2012-06-27 Impact factor: 9.910
Authors: Cynthia Kwan; Imane Frouni; Dominique Bédard; Stephen G Nuara; Jim C Gourdon; Adjia Hamadjida; Philippe Huot Journal: Exp Brain Res Date: 2018-11-15 Impact factor: 1.972
Authors: Cynthia Kwan; Stephen G Nuara; Jim C Gourdon; Philippe Huot Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2021-05-08 Impact factor: 3.000